Yujun joined Crown as an experienced immunologist/immuno-oncologist, with extensive subject matter expertise inthe IO field,from drug discovery to early clinical development, for both small molecules and biologicals, as well as biomarkers. Before joiningCrown, Yujunwas an Associate Director of Translational Medicine at Oncomed Pharmaceuticals in San Francisco Bay areawhere he supported the development of IO biomarkers in preclinical and clinical settings foranti-TIGIT monoclonal antibody. Previously,he was a Principal Scientist at Halozyme Therapeutics in San Diego, where he led the in vivo pharmacology IO team to support the preclinical development of Pegvorhyaluronidase α-PEGPH20 combined with cancer immunotherapy;he also led the IO research at Pharmacyclics, an Abbvie company in Silicon Valley.Yujun’s academic background includes a PhD in immunology at Loyola University Chicago, a BS in Medicine and a MS in Surgical Pathology from Fudan University (formerly Shanghai Medical University). His PhD work was focused on tumor immunology and cancer vaccine. He received his postdoc training at La Jolla Institute for Immunology, a world leader in immunology research. His research was focused on tissue-resident T cells in cancer, infectious diseases and autoimmune diseases. His work was published intop-tier immunology journals and hasprovided technical leadership across multiple immuno-oncology programs. He initiated and led preclinical in vitro and in vivo pharmacology studies for small molecule drug Ibrutinib and other tyrosine kinase inhibitors, as well as IO combination therapies.
